Health-Related Quality of Life With Trastuzumab Monotherapy Versus Trastuzumab Plus Standard Chemotherapy as Adjuvant Therapy in Older Patients With HER2-Positive Breast Cancer Between September 2006 ...

Adrenocortical carcinoma is a rare heterogeneous neoplasm with an incompletely understood pathogenesis and a poor prognosis. Previous studies have identified overexpression of insulin-like growth ...

Adrenocortical carcinoma is a rare cancer that has a poor response to cytotoxic treatment. We randomly assigned 304 patients with advanced adrenocortical carcinoma to receive mitotane plus either a ...

Doctors divide adrenocortical carcinoma into four stages, depending on how far the cancer has spread and which tissues it affects. This helps inform decisions about treatment and outlook.

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Of a cohort of adults with adrenocortical cancer, 38.1% ...

Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features Adrenocortical carcinomas ...

Alkindi® Sprinkle (hydrocortisone) will be available as 0.5mg, 1mg, 2mg, and 5mg oral granules. The Food and Drug Administration (FDA) has approved Alkindi® Sprinkle (hydrocortisone oral granules; ...

In 2017, the teams of Massimo Terzolo and Martin Fassnacht published a study in the New England Journal of Medicine that provided evidence for the efficacy of Mitotane in the prevention of recurrence ...

Adrenocortical function is not impaired in patients with pernicious anemia in relapse, as judged by the changes in the plasma 17-hydroxycorticosteroids after ACTH administration. Except for the lack ...

Adrenocortical carcinoma (ACC) is a rare but aggressive malignancy with high postoperative recurrence rates and poor prognosis. Mitotane remains the only approved agent for ACC, exerting antitumor ...